Keytruda (Pembrolizumab) Denied: Appealing PD-L1, MSI-H, and Off-Label Cancer Treatment Denials

Keytruda (pembrolizumab) is one of the most widely used cancer immunotherapies in the world. It is FDA-approved for more than 40 indications spanning lung, head and neck, bladder, kidney, endometrial, cervical, gastric, colorectal, skin, breast, and other cancers — as well as a tumor-agnostic indication for MSI-H/dMMR solid tumors. Despite its broad approvals, insurance denials for Keytruda are common and often reflect technical arguments around biomarker testing, line of therapy, and documentation. Here is how to build an effective appeal.

Why Keytruda Gets Denied

PD-L1 expression thresholds. For non-small cell lung cancer, certain Keytruda regimens require PD-L1 expression ≥ 1% or ≥ 50% depending on the specific indication (monotherapy vs. combination). Insurers routinely deny if PD-L1 testing was not performed with an FDA-approved companion diagnostic (the 22C3 pharmDx assay for most lung cancer indications). If the test was done using a different assay, the insurer may deny on technicality even when results are positive.

MSI-H/dMMR and TMB-H criteria. The tumor-agnostic Keytruda approvals for MSI-H/dMMR (mismatch repair deficient) and TMB-H (≥10 mutations/megabase) solid tumors are powerful, but insurers frequently deny when the testing laboratory is not considered validated, or when the tumor type is one where the clinical benefit data is limited.

Line of therapy disputes. Some Keytruda indications are approved for first-line therapy, others for second-line or later. Insurers sometimes deny when the prescriber is using Keytruda earlier or differently than the specific approved line, citing the clinical benefit has not been demonstrated in that setting.

Combination vs. monotherapy mismatches. Keytruda is frequently prescribed in combination with chemotherapy, targeted agents, or other biologics. If the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization request describes one regimen and the prescription reflects a slightly different combination, insurers use the discrepancy as grounds for denial.

Off-label use in solid tumors. Although NCCN guidelines list Keytruda as a recommended option for many tumor types and settings beyond its FDA approvals, insurers often require the specific FDA-approved indication to be matched exactly.

How to Appeal a Keytruda Denial

Step 1: Identify which biomarker test was used. Request copies of the pathology reports showing PD-L1 expression, MSI status, dMMR testing, and TMB results. Confirm the testing platform. If the denial cites the wrong platform, your oncologist can request a reflex test using the FDA-approved companion diagnostic.

Step 2: Match the indication precisely. Pull the FDA label for pembrolizumab and identify the exact indication that applies to your cancer type, stage, line of therapy, and biomarker status. Your appeal must quote this language directly and match every parameter.

Step 3: Use NCCN guidelines for off-label claims. Most state insurance laws and many commercial plans define "medically necessary" to include treatments recommended by recognized compendia like NCCN. If Keytruda is listed as a Category 1 or Category 2A recommendation for your cancer type in NCCN guidelines, your appeal should cite this directly, even if the indication is technically off-label.

Step 4: Request expedited review. For cancer patients, most states require insurance companies to provide expedited appeal decisions within 72 hours when the standard appeal timeline would seriously jeopardize the patient's health. File for expedited review in every case.

Step 5: Involve your oncologist in a peer-to-peer. Oncologists routinely win peer-to-peer reviews for Keytruda denials because the clinical evidence supporting immunotherapy is overwhelming and the denying reviewer is often not an oncologist. Insist your treating physician request this call.

The Tumor-Agnostic Argument

If your cancer is MSI-H/dMMR or TMB-H, you have access to one of the most powerful insurance appeal arguments in oncology. These approvals do not depend on tumor type — they depend on the molecular characteristics of the tumor. If your insurer denies Keytruda for a cancer type that is not listed in the label but your tumor has confirmed MSI-H/dMMR status, the denial is almost certainly incorrect and should be appealed immediately.

Fight Back With ClaimBack

A Keytruda denial in the middle of cancer treatment is not just a financial issue — it is a medical emergency. ClaimBack helps oncology patients and their caregivers build biomarker-specific, indication-matched appeal letters that cut through insurer technical denials.

Start your Keytruda appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?